Liu Mingsheng, Xing Yan, Tan Jiufeng, Chen Xiaoliang, Xue Yaming, Qu Licheng, Ma Jianchao, Jin Xuefei
2nd Inpatient Area of Urology Department, China-Japan Union Hospital, Jilin University, Changchun, China.
Jinlin Provincial Key Laboratory of Molecular Diagnosis of Urological Tumors, Changchun, China.
Front Cell Dev Biol. 2024 Jul 26;12:1442052. doi: 10.3389/fcell.2024.1442052. eCollection 2024.
PBX1 is a transcription factor that can promote the occurrence of various tumors and play a reg-ulatory role in tumor growth, metastasis, invasion, and drug resistance. Furthermore, a variant generated by fusion of E2A and PBX1, E2A-PBX1, has been found in 25% of patients with childhood acute lymphoblastic leukemia. Thus, PBX1 is a potential therapeutic target for many cancers. Here, we describe the structure of PBX1 and E2A-PBX1 as well as the molecular mecha-nisms whereby these proteins promote tumorigenesis to provide future research directions for developing new treatments. We show that PBX1 and E2A-PBX1 induce the development of highly malignant and difficult-to-treat solid and blood tumors. The development of specific drugs against their targets may be a good therapeutic strategy for PBX1-related cancers. Furthermore, we strongly recommend E2A-PBX1 as one of the genes for prenatal screening to reduce the incidence of childhood hematological malignancies.
PBX1是一种转录因子,可促进各种肿瘤的发生,并在肿瘤生长、转移、侵袭和耐药性方面发挥调节作用。此外,在25%的儿童急性淋巴细胞白血病患者中发现了由E2A和PBX1融合产生的变体E2A-PBX1。因此,PBX1是许多癌症潜在的治疗靶点。在此,我们描述了PBX1和E2A-PBX1的结构以及这些蛋白质促进肿瘤发生的分子机制,以为开发新疗法提供未来的研究方向。我们表明,PBX1和E2A-PBX1会诱导高恶性且难以治疗的实体瘤和血液肿瘤的发展。开发针对其靶点的特异性药物可能是治疗PBX1相关癌症的良好策略。此外,我们强烈推荐将E2A-PBX1作为产前筛查的基因之一,以降低儿童血液系统恶性肿瘤的发病率。